Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
about
Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions.Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.Clinicopathological and EBV analysis of respiratory epithelial adenomatoid hamartomaA drug-repositioning screening identifies pentetic acid as a potential therapeutic agent for suppressing the elastase-mediated virulence of Pseudomonas aeruginosa.Vitamin B12-mediated restoration of defective anaerobic growth leads to reduced biofilm formation in Pseudomonas aeruginosa.Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis.A novel siderophore system is essential for the growth of Pseudomonas aeruginosa in airway mucusIdentification of essential genes of Pseudomonas aeruginosa for its growth in airway mucus.The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review.
P2860
Q30447266-1239CDFD-D5E4-494B-817A-8EA24B1C466FQ33550582-826F27A5-C9A8-4158-BADC-C75618CA9C1DQ33574479-8FCD7FC1-8DA2-497F-ACA8-C8A1F9BCB6A9Q35270008-D9E2D251-62DE-48E8-A779-905083B5D06BQ35944028-838D2204-6853-40D0-8E5C-7449CB67AB37Q36107786-68BCDDF8-5680-4A53-B6ED-D5C5F43FA01CQ36134138-679DFC69-9AD5-47AC-8751-2C4748071D54Q36236143-726C2F32-C719-47F0-9D27-D7BA5CE90B93Q36808070-0AE89891-30A1-4A92-A9B8-28C937AFB843Q40021908-69C3F066-7F51-45EF-A595-C0FFE6B7CFA7Q54205022-90D94F0C-073E-4EB6-A8EB-209F1B503352
P2860
Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@ast
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@en
type
label
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@ast
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@en
prefLabel
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@ast
Chronic Pseudomonas aeruginosa ...... at unravel novel drug targets.
@en
P2860
P356
P1476
Chronic Pseudomonas aeruginosa ...... hat unravel novel drug targets
@en
P2093
Daniel J Hassett
P2860
P304
P356
10.1586/14787210.2.4.611
P577
2004-08-01T00:00:00Z